Navigation Links
Halozyme Therapeutics Announces Executive Transitions
Date:12/17/2013

SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Helen Torley, M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief Executive Officer on January 6, 2014. She will also become a member of Halozyme's Board of Directors. Dr. Torley was most recently Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen. Gregory I. Frost, Ph.D. is departing Halozyme for Intrexon (NYSE: XON), assuming the head of that company's Health Sector, and will continue to lead Halozyme's Scientific Advisory Board. Dr. Frost will join Intrexon effective January 6, 2014.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"Helen's demonstrated leadership of Onyx's oncology products will build on Halozyme's trajectory of value creation, pivoting from partnered to proprietary products," said Kenneth J. Kelley, Chairman of the Board of Directors of Halozyme. "She brings over 20 years of successful brand development and launch expertise garnered from key roles at other companies, including Amgen and Bristol Myers Squibb."

Prior to Onyx, Dr. Torley spent 14 years in management positions at Amgen, first in the Nephrology Business Unit, later in the Bone Health Business Unit. She held various senior positions at Bristol Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales, and Head of Cardiovascular Global Marketing. She began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing clinical studies across all therapeutic areas, including oncology.

In reflecting on his 15 years at Halozyme, Dr. Frost said, "I am very proud of the multiple scientific, development, and regulatory milestones the team has achieved to date. I look forward to supporting Halozyme's next chapter of transformative healthcare in my capacity of leading the Scientific Advisory Board." 

"It is truly an honor to be joining Halozyme," said Dr. Torley. "I am excited by the unique portfolio of proprietary products in clinical testing for the treatment of cancer, diabetes and cellulite, and by the multiple royalty-based partnerships that clearly point to a talented team with a proven track record."

RJ Kirk, Halozyme's largest shareholder and member of the Board of Directors commented, "Halozyme has successfully transitioned over the last several years from being science-driven to become commercially-oriented. This is a very fortunate position to be in for any company. I laud the efforts by Greg in leading the Company to its present position with multiple product approvals under its belt. Halozyme's advanced, proprietary products are game-changing for the Company, and we must be prepared to maximize the realization of its commercial opportunities. Helen is an ideal choice to lead the company at this important moment in its trajectory."

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on Twitter @HaloTherapeutic.

Safe Harbor Statement 
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning Halozyme's intended business plan and the possible benefit and attributes of its products and technologies.  The forward-looking statements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment, conduct and results, unexpected adverse events and outcomes, unexpected expenditures and costs and unexpected results or delays in development and regulatory review. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2013 under Risk Factors. Halozyme does not undertake to update these forward-looking statements.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260 
ir@halozyme.com

Media Contact:
Tali Mackay
Hill+Knowlton Strategies
310-633-9495
Tali.Mackay@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
2. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
3. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
4. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
5. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
6. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
7. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
8. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
9. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
10. Halozyme Reports Second Quarter 2013 Financial Results
11. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Hemophilia market? What are the unit prices and ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation ... and body, these individual customized retreats offer the winter-weary soul an excellent opportunity ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has ... a company involved in the underground testing of nuclear weapons. Years later, when her ... Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by ...
(Date:2/27/2017)... ... 27, 2017 , ... Orange County dentist, Dr. A. Rassouli, comments ... occurs when the bacteria in plaque infect the gums and other tissues supporting the ... root planing or SRP, and can include surgical therapies if the condition has led ...
(Date:2/27/2017)... ... , ... Miro is the ultimate smart media center that offers a fascinating ... shows and much more apps for user exploration. Its innovative acoustic design with premium ... x 720 provides crisp images with remarkable clarity and color. The WiFi connection enables ...
(Date:2/27/2017)... Houston, TX (PRWEB) , ... February 27, 2017 ... ... the 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential ... Volterra Energy LLC in March 2014. The company had 800 customers and 2,250 ...
Breaking Medicine News(10 mins):